Melanoma Clinical Trials in Maryland

Showing 221-240 of 354 trials

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

NCT02423863

The purpose of this study is to evaluate the safety of sequential intratumoral (IT) plus intramuscular (IM) Polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC, Hiltonol®) for treatment of study subjects with accessible solid tumors, with or without checkpoint blockers. Enrolled study subjects will receive Poly-ICLC (Hiltonol®) treatment alone or in combination with anti-PD-1 (Nivolumab, Pembrolizumab or Cemiplimab) or anti-PD-L1 (Atezolizumab or Durvalumab) over 6 months as defined in study treatment described below. MRI or CT imaging will be done per SOC at screening, 3 and 6-month time points.

MelanomaHead and Neck CancerSarcoma+1 more

Oncovir, Inc.26 participantsStarted Mar 2015

Chevy Chase, Maryland, United States • Chevy Chase, Maryland, United States • Easton, Maryland, United States +2 more locations

COMPLETED15 miles

Development and Validation of a New Digital Dermatoscope in the United States

NCT04047316

A completely new type of digital dermatoscope has been developed in order to take a significant step forward in technology for skin cancer imaging. By means of this study a better insight can be gained of the current performance and workflow in clinical dermatoscopy. This knowledge will be used to further improve the developed technology.

Skin Cancer

Barco NV60 participantsStarted Aug 2019

Chevy Chase, Maryland, United States • Salem, Oregon, United States

In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®

Development and Validation of a New Digital Dermatoscope in the United States

Melanoma Trials in Other Cities

Sun Exposure and Melanoma in Agricultural Workers

Molecular Epidemiology of Cutaneous Malignant Melanoma

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

Other Conditions in Maryland